Oxazines

Antiviral Agents
Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients
Marc Wirden, Bénédicte Roquebert, Anne Derache, Anne Simon, Claudine Duvivier, Jade Ghosn, Stephanie Dominguez, Véronique Boutonnet, Zaina Ait-Arkoub, Christine Katlama, Vincent Calvez, Anne-Genevieve Marcelin
Clinical Therapeutics
Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors
Patrick F. Smith, Gregory K. Robbins, Robert W. Shafer, Hulin Wu, Song Yu, Martin S. Hirsch, Thomas C. Merigan, Jeong-Gun Park, Alan Forrest, Margaret A. Fischl, Gene D. Morse, the ACTG 384-5006 Team
Antiviral Agents
Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir in Seronegative Individuals
Gene D. Morse, Susan Rosenkranz, Michael F. Para, Yoninah Segal, Robin DiFrancesco, Elizabeth Adams, Barbara Brizz, Kevin E. Yarasheski, Richard C. Reichman
and the ACTG 5043 Protocol Team
Susceptibility
Microplate Alamar Blue Assay for Staphylococcus epidermidis Biofilm Susceptibility Testing
Robin K. Pettit, Christine A. Weber, Melissa J. Kean, Holger Hoffmann, George R. Pettit, Rui Tan, Kelly S. Franks, Marilyn L. Horton
Clinical Therapeutics
Pharmacokinetics of Indinavir at 800, 600, and 400 Milligrams Administered with Ritonavir at 100 Milligrams and Efavirenz in Ethnic Chinese Patients Infected with Human Immunodeficiency Virus
Lawrence S. Lee, Anushia Panchalingam, Marline C. Yap, Nicholas I. Paton
Antiviral Agents
Effects of Valproic Acid Coadministration on Plasma Efavirenz and Lopinavir Concentrations in Human Immunodeficiency Virus-Infected Adults
Robert DiCenzo, Derick Peterson, Kim Cruttenden, Gene Morse, Garret Riggs, Harris Gelbard, Giovanni Schifitto
Antiviral Agents
Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1
Michael J. Hofman, Joanne Higgins, Timothy B. Matthews, Niels C. Pedersen, Chalet Tan, Raymond F. Schinazi, Thomas W. North
Mechanisms of Action: Physiological Effects
Screening for Microtubule-Disrupting Antifungal Agents by Using a Mitotic-Arrest Mutant of Aspergillus nidulans and Novel Action of Phenylalanine Derivatives Accompanying Tubulin Loss
Tetsuo Kiso, Ken-Ichi Fujita, Xu Ping, Toshio Tanaka, Makoto Taniguchi
Pharmacology
Intrapatient Variability of Efavirenz Concentrations as a Predictor of Virologic Response to Antiretroviral Therapy
Richard C. Brundage, Florence H. Yong, Terence Fenton, Stephen A. Spector, Stuart E. Starr, Courtney V. Fletcher
Susceptibility
Resazurin Microtiter Assay Plate Testing of Mycobacterium tuberculosis Susceptibilities to Second-Line Drugs: Rapid, Simple, and Inexpensive Method
Anandi Martin, Mirtha Camacho, Françoise Portaels, Juan Carlos Palomino

Pages